Kamada Ltd
Research Kamada Ltd (KMDA) on Bullrun: valuation model: fairly valued, market cap USD 497.83M, P/E 24.7, dividend yield 3.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKMDA
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signalfairly valued
- Market capUSD 497.83M
- P/E24.7
- Dividend yield3.0%
- Financial periodQ1 2026
- RevenueUSD 45.24M
- Net incomeUSD 4.13M
- Free cash flowUSD 16.36M
- Gross margin42.3%
Valuation Snapshot
Bullrun's latest valuation model marks Kamada Ltd as fairly valued; latest market cap is USD 497.83M; P/E is 24.7; dividend yield is 3.0%.
Peer valuation comparison
Latest P/E is 24.69x versus a Healthcare sector median of 24.46x.
Latest dividend yield is 3.03% versus a Healthcare sector median of 2.11% (43.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 180.46M | USD 20.20M | USD 15.64M | 42.3% | 0.35 | USD 75.47M | USD 11.56M | USD 269.07M |
| FY2024 | USD 160.95M | USD 14.46M | USD 36.85M | 43.5% | 0.26 | USD 78.44M | USD 11.06M | USD 259.46M |
| FY2023 | n/a | n/a | n/a | n/a | 0.21 | USD 55.64M | USD 8.82M | USD 244.02M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 497.83M | 24.7 | 2.9% | 0.25 |
| 2025 | 2025-12-31 | USD 407.26M | 20.2 | 2.8% | 0.2 |
| 2024 | 2024-12-31 | USD 350.21M | 24.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 351.75M | 47.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 179.65M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 294.78M | n/a | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.25 USD, yield 3.0%.
About Kamada Ltd
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Kamada Ltd overvalued or undervalued?
Bullrun's valuation model currently marks Kamada Ltd as fairly valued.
What is Kamada Ltd's market cap?
Kamada Ltd's market capitalization is USD 497.83M.
What is Kamada Ltd's P/E ratio?
Kamada Ltd's price-to-earnings (P/E) ratio is 24.7.
Does Kamada Ltd pay a dividend?
Kamada Ltd has a dividend yield of 3.0%.
What does Kamada Ltd do?
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns;.